Platelet count in essential thrombocythemia: the more the better?

Por Tefferi, Ayalew
Publicado em 2008

Editor's Note: Conflicts of Interest at Medical Journals

Por Tefferi, Ayalew
Publicado em 2010

Myelodysplastic Syndromes—Many New Drugs, Little Therapeutic Progress

Por Tefferi, Ayalew
Publicado em 2010

Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1

Por Tefferi, Ayalew
Publicado em 2009

Prognostic relevance of anemia and transfusion dependency in myelodysplastic syndromes and primary myelofibrosis

Por Pardanani, Animesh, Tefferi, Ayalew
Publicado em 2011

Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis

Por Tefferi, Ayalew, Pardanani, Animesh
Publicado em 2011

Myeloproliferative neoplasms biology and therapy /

Por Verstovsek, Srdan, Tefferi, Ayalew
Publicado em c201

Myeloproliferative neoplasms critical concepts and management /

Por Barbui, Tiziano, Tefferi, Ayalew
Publicado em c201

Refractory Anemia with Ring Sideroblasts (RARS) and RARS with Thrombocytosis (RARS-T) – “2017 Update on Diagnosis, Risk-stratification, and Management”

Por Patnaik, Mrinal M., Tefferi, Ayalew
Publicado no Am J Hematol (2017)

Hypereosinophilic Syndrome and Clonal Eosinophilia: Point-of-Care Diagnostic Algorithm and Treatment Update

Por Tefferi, Ayalew, Gotlib, Jason, Pardanani, Animesh
Publicado em 2010

Uses and Abuses of JAK2 and MPL Mutation Tests in Myeloproliferative Neoplasms: A Paper from the 2010 William Beaumont Hospital Symposium on Molecular Pathology

Por Tefferi, Ayalew, Noel, Pierre, Hanson, Curtis A.
Publicado em 2011

Outcome of Splenectomy for Thrombocytopenia Associated With Systemic Lupus Erythematosus

Por You, Y Nancy, Tefferi, Ayalew, Nagorney, David M.
Publicado em 2004

Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms

Por Abdel-Wahab, Omar, Tefferi, Ayalew, Levine, Ross L.
Publicado em 2012

Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F

Por Gery, Sigal, Cao, Qi, Gueller, Saskia, Xing, Hongtao, Tefferi, Ayalew, Koeffler, H. Phillip
Publicado em 2009

Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked

Por Elliott, Michelle Ann, Pardanani, Animesh, Lasho, Terra L., Schwager, Susan M., Tefferi, Ayalew
Publicado em 2010

Case of chronic eosinophilic leukemia with deletion of chromosome 16 and hepatitis C.

Por Kamineni, Padma, Baptiste, Ayanna, Hassan, Mukhtar, Dawkins, Fitzroy W., Zaidi, Syed, Tefferi, Ayalew, Lindsey, Mercedes, Taddesse-Heath, Lekidelu
Publicado em 2006

Mature Survival Data for 176 Patients Younger Than 60 Years With Primary Myelofibrosis Diagnosed Between 1976 and 2005: Evidence for Survival Gains in Recent Years

Por Vaidya, Rakhee, Siragusa, Sergio, Huang, Jocelin, Schwager, Susan M., Hanson, Curtis A., Hussein, Kebede, Pardanani, Animesh, Tefferi, Ayalew
Publicado em 2009

If you feed them, they will come: A prospective study of the effects of complimentary food on attendance and physician attitudes at medical grand rounds at an academic medical cent...

Por Segovis, Colin M, Mueller, Paul S, Rethlefsen, Melissa L, LaRusso, Nicholas F, Litin, Scott C, Tefferi, Ayalew, Habermann, Thomas M
Publicado em 2007

TG101209, a novel JAK2 inhibitor, has significant in-vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells

Por Ramakrishnan, Vijay, Kimlinger, Teresa, Haug, Jessica, Timm, Michael, Wellik, Linda, Halling, Timothy, Pardanani, Animesh, Tefferi, Ayalew, Rajkumar, S. Vincent, Kumar, Shaji
Publicado em 2010

European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis....

Por Thiele, Jürgen, Orazi, Attilio, Kvasnicka, Hans Michael, Franco, Vito, Boveri, Emanuela, Gianelli, Umberto, Gisslinger, Heinz, Passamonti, Francesco, Tefferi, Ayalew, Barbui, Tiziano
Publicado em 2012